MELBOURNE, AUSTRALIA--(Marketwire - July 29, 2008) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced today the publication of the results of its Phase 2a clinical trial on Alzheimer's disease patients in The Lancet Neurology journal.